JAM
INDV icon

Jupiter Asset Management’s Indivior Pharmaceuticals INDV Stock Holding History

Jupiter Asset Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-358,745
Closed -$5.42M – 473
2023
Q4 		$5.42M Sell
358,745
-130,844
-27% -$2.32M 0.05% 251
2023
Q3 		$10.6M Sell
489,589
-169,014
-26% -$3.85M 0.12% 195
2023
Q2 		$15.3M Buy
+658,603
New +$15.1M 0.17% 164

Other funds holding INDV

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Jupiter Asset Management's INDV Position: Q1 2024 in Review

Jupiter Asset Management sold out of Indivior Pharmaceuticals (INDV) in Q1 2024, closing a stake of 358,745 shares — an estimated $5.42M sold.

Jupiter Asset Management first reported a position in INDV in Q2 2023 and held it in 3 quarters. The position peaked at $15.3M in Q2 2023. 95 funds tracked by Wall St. Rank hold INDV as of Q1 2024.

  • Jupiter Asset Management reported no remaining Indivior Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Jupiter Asset Management sold 358,745 Indivior Pharmaceuticals shares in Q1 2024, an estimated $5.42M.
  • Jupiter Asset Management first reported a position in Indivior Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • Jupiter Asset Management's Indivior Pharmaceuticals position peaked at $15.3M in Q2 2023.
  • 95 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2024.

Based on Jupiter Asset Management's 13F filing for Q1 2024, filed 10 May 2024.